KISSEI PHARMACEUTICAL CO.,LTD. Logo

KISSEI PHARMACEUTICAL CO.,LTD.

A research-driven pharmaceutical firm focused on urology, renal, and rare diseases.

4547 | T

Overview

Corporate Details

ISIN(s):
JP3240600001
LEI:
Country:
Japan
Address:
松本市芳野19番48号

Description

Kissei Pharmaceutical Co., Ltd. is a research-driven company engaged in the discovery, development, manufacturing, and sale of pharmaceutical products. The company concentrates its research and development investments in key therapeutic areas, including urology, renal diseases and dialysis, and rare or intractable diseases. Its broader product portfolio also addresses conditions in metabolic and endocrinological, obstetrics and gynecological, and ophthalmic fields. Committed to creating innovative medicines, Kissei aims to contribute to global health by addressing unmet medical needs. The company also operates in the health foods sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 08:34
確認書
Japanese 8.9 KB
2025-11-10 08:33
半期報告書-第81期(2025/04/01-2026/03/31)
Japanese 236.4 KB
2025-06-27 06:00
臨時報告書
Japanese 23.3 KB
2025-06-24 06:01
確認書
Japanese 9.0 KB
2025-06-24 06:01
内部統制報告書-第80期(2024/04/01-2025/03/31)
Japanese 25.5 KB
2025-06-24 06:00
有価証券報告書-第80期(2024/04/01-2025/03/31)
Japanese 1.5 MB
2025-06-11 06:00
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2024-12-27 08:00
大量保有報告書
Japanese 38.5 KB
2024-12-13 05:00
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2024-11-13 05:01
確認書
Japanese 9.0 KB
2024-11-13 05:00
半期報告書-第80期(2024/04/01-2025/03/31)
Japanese 240.5 KB
2024-06-28 06:00
臨時報告書
Japanese 29.4 KB
2024-06-25 06:01
内部統制報告書-第79期(2023/04/01-2024/03/31)
Japanese 23.8 KB
2024-06-25 06:00
確認書
Japanese 9.0 KB
2024-06-25 06:00
有価証券報告書-第79期(2023/04/01-2024/03/31)
Japanese 1.5 MB

Automate Your Workflow. Get a real-time feed of all KISSEI PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KISSEI PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KISSEI PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.